The U.S. Food and Drug Administration issued a Complete Response Letter to UCB regarding the Belgium-based company’s Biologics License Application for bimekizumab for adults with moderate to severe plaque psoriasis.
Novartis boss Vas Narasimhan expects higher sales and profitability for 2020, lifted by the company’s broad range of medicines, and minimal disruption to the Swiss drugmaker’s supply chain from the coronavirus outbreak in China.
Vical Incorporated and Brickell Biotech Inc. announced a definitive merger agreement under which Brickell would merge with a wholly owned subsidiary of Vical in an all-stock transaction.
